Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 13

1.

Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials.

Hua X, Hibar DP, Ching CR, Boyle CP, Rajagopalan P, Gutman BA, Leow AD, Toga AW, Jack CR Jr, Harvey D, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2013 Feb 1;66:648-61. doi: 10.1016/j.neuroimage.2012.10.086. Epub 2012 Nov 12.

2.

APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease.

Reinvang I, Espeseth T, Westlye LT.

Neurosci Biobehav Rev. 2013 Sep;37(8):1322-35. doi: 10.1016/j.neubiorev.2013.05.006. Epub 2013 May 20. Review.

3.

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Hampel H, B├╝rger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K.

Alzheimers Dement. 2008 Jan;4(1):38-48. doi: 10.1016/j.jalz.2007.08.006. Epub 2007 Dec 21. Review.

PMID:
18631949
4.

Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease.

Teipel SJ, Grothe M, Lista S, Toschi N, Garaci FG, Hampel H.

Med Clin North Am. 2013 May;97(3):399-424. doi: 10.1016/j.mcna.2012.12.013. Epub 2013 Feb 1. Review.

PMID:
23642578
5.

The role of diffusion tensor imaging in detecting microstructural changes in prodromal Alzheimer's disease.

Zhang B, Xu Y, Zhu B, Kantarci K.

CNS Neurosci Ther. 2014 Jan;20(1):3-9. doi: 10.1111/cns.12166. Epub 2013 Dec 12. Review.

PMID:
24330534
6.

Tracking Alzheimer's disease.

Thompson PM, Hayashi KM, Dutton RA, Chiang MC, Leow AD, Sowell ER, De Zubicaray G, Becker JT, Lopez OL, Aizenstein HJ, Toga AW.

Ann N Y Acad Sci. 2007 Feb;1097:183-214. Review.

7.

Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans.

Saykin AJ, Shen L, Yao X, Kim S, Nho K, Risacher SL, Ramanan VK, Foroud TM, Faber KM, Sarwar N, Munsie LM, Hu X, Soares HD, Potkin SG, Thompson PM, Kauwe JS, Kaddurah-Daouk R, Green RC, Toga AW, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Jul;11(7):792-814. doi: 10.1016/j.jalz.2015.05.009. Review.

8.

Disrupted structural and functional brain connectomes in mild cognitive impairment and Alzheimer's disease.

Dai Z, He Y.

Neurosci Bull. 2014 Apr;30(2):217-32. doi: 10.1007/s12264-013-1421-0. Epub 2014 Apr 15. Review.

PMID:
24733652
9.

Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative.

Jack CR Jr, Bernstein MA, Borowski BJ, Gunter JL, Fox NC, Thompson PM, Schuff N, Krueger G, Killiany RJ, Decarli CS, Dale AM, Carmichael OW, Tosun D, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 May;6(3):212-20. doi: 10.1016/j.jalz.2010.03.004. Review.

10.

Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's Disease Neuroimaging Initiative 2 participants.

Franklin EE, Perrin RJ, Vincent B, Baxter M, Morris JC, Cairns NJ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Jul;11(7):815-22. doi: 10.1016/j.jalz.2015.05.010. Review.

PMID:
26194314
11.

Neuroimaging in Alzheimer's disease: preclinical challenges toward clinical efficacy.

Dustin D, Hall BM, Annapragada A, Pautler RG.

Transl Res. 2016 Mar 12. pii: S1931-5244(16)00084-0. doi: 10.1016/j.trsl.2016.03.005. [Epub ahead of print] Review.

PMID:
27033146
12.
13.

Treatment trials in aging and mild cognitive impairment.

Corey-Bloom J.

Curr Top Behav Neurosci. 2012;10:347-56. doi: 10.1007/7854_2011_153. Review.

PMID:
21786037
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk